Literature DB >> 20671603

MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers.

Mohamed El Ayed1, David Bonnel, Remi Longuespée, Céline Castelier, Julien Franck, Daniele Vergara, Annie Desmons, Aurélie Tasiemski, Abderraouf Kenani, Denis Vinatier, Robert Day, Isabelle Fournier, Michel Salzet.   

Abstract

BACKGROUND: Among biomarkers, cancer-antigen 125 (CA-125) is the most studied. We propose an analytical tool to track ovarian carcinoma biomarkers, that is, the MALDI mass spectrometry imaging. MATERIAL/
METHODS: Ovarian carcinomas and benign ovaries were directly analyzed by MALDI-TOF-MS. After automatic profiling and mass spectrometry imaging analyses, hierarchical clustering based on principal component analysis in nonsupervised mode was carried out. On the same samples, preparations were performed to investigate peptides, then proteins, followed by high mass proteins, in an automatic profiling to specific signatures for diagnosis. Using tissue bottom-up strategy on tissue digestion, and mass spectrometry imaging after by shotgun sequencing by nalano-LC-IT-MS in MS/MS mode from washing samples from on tissue digested peptides, several biomarkers were found.
RESULTS: A list of specific biomarkers from the ovarian carcinoma regions was obtained and classified as proteins associated with cell proliferation, involved in immune response modulation, signaling to the cytoskeleton, and tumor progression. These specific biomarkers were then validated by immunocytochemistry using Tag-mass technology, cell biology, Western blot, and by PCR (using SKOV-3 ovarian epithelial cancer cells). A link between the immune regulation (innate immunity, tolerance) and virus cause is also discussed.
CONCLUSIONS: From the biomarkers identified, proteins involved in immune response modulation and cell proliferation have been pointed out in this study. Two new markers have been identified using such a strategy, that is, fragment C-terminal of the PSME1 (Reg-Alpha) and mucin-9.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20671603

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  25 in total

1.  The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling.

Authors:  Rémi Longuespée; Charlotte Boyon; Céline Castellier; Amélie Jacquet; Annie Desmons; Olivier Kerdraon; Denis Vinatier; Isabelle Fournier; Robert Day; Michel Salzet
Journal:  Histochem Cell Biol       Date:  2012-04-25       Impact factor: 4.304

Review 2.  MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications.

Authors:  Benjamin Balluff; Cedrik Schöne; Heinz Höfler; Axel Walch
Journal:  Histochem Cell Biol       Date:  2011-07-30       Impact factor: 4.304

3.  HFIP extraction followed by 2D CTAB/SDS-PAGE separation: a new methodology for protein identification from tissue sections after MALDI mass spectrometry profiling for personalized medicine research.

Authors:  Rémi Longuespée; Christophe Tastet; Annie Desmons; Olivier Kerdraon; Robert Day; Isabelle Fournier; Michel Salzet
Journal:  OMICS       Date:  2014-05-19

4.  Protein identification in imaging mass spectrometry through spatially targeted liquid micro-extractions.

Authors:  Daniel J Ryan; David Nei; Boone M Prentice; Kristie L Rose; Richard M Caprioli; Jeffrey M Spraggins
Journal:  Rapid Commun Mass Spectrom       Date:  2018-03-15       Impact factor: 2.419

Review 5.  Unsupervised machine learning for exploratory data analysis in imaging mass spectrometry.

Authors:  Nico Verbeeck; Richard M Caprioli; Raf Van de Plas
Journal:  Mass Spectrom Rev       Date:  2019-10-11       Impact factor: 10.946

6.  Automated querying and identification of novel peptides using MALDI mass spectrometric imaging.

Authors:  Jocelyne Bruand; Srinivas Sistla; Céline Mériaux; Pieter C Dorrestein; Terry Gaasterland; Majid Ghassemian; Maxence Wisztorski; Isabelle Fournier; Michel Salzet; Eduardo Macagno; Vineet Bafna
Journal:  J Proteome Res       Date:  2011-03-15       Impact factor: 4.466

Review 7.  Recent advances in single-cell MALDI mass spectrometry imaging and potential clinical impact.

Authors:  Kristin J Boggio; Emmanuel Obasuyi; Ken Sugino; Sacha B Nelson; Nathalie Yr Agar; Jeffrey N Agar
Journal:  Expert Rev Proteomics       Date:  2011-10       Impact factor: 3.940

8.  Gold nanorods for ovarian cancer detection with photoacoustic imaging and resection guidance via Raman imaging in living mice.

Authors:  Jesse V Jokerst; Adam J Cole; Dominique Van de Sompel; Sanjiv S Gambhir
Journal:  ACS Nano       Date:  2012-11-02       Impact factor: 15.881

9.  Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.

Authors:  David Sánchez-Martín; Jorge Martínez-Torrecuadrada; Tambet Teesalu; Kazuki N Sugahara; Ana Alvarez-Cienfuegos; Pilar Ximénez-Embún; Rodrigo Fernández-Periáñez; M Teresa Martín; Irene Molina-Privado; Isabel Ruppen-Cañás; Ana Blanco-Toribio; Marta Cañamero; Angel M Cuesta; Marta Compte; Leonor Kremer; Carmen Bellas; Vanesa Alonso-Camino; Irene Guijarro-Muñoz; Laura Sanz; Erkki Ruoslahti; Luis Alvarez-Vallina
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

Review 10.  In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Authors:  Joshua G Cohen; Matthew White; Ana Cruz; Robin Farias-Eisner
Journal:  World J Biol Chem       Date:  2014-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.